(NASDAQ: ALXO) Alx Oncology Holdings's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 78.36%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.83%.
Alx Oncology Holdings's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast ALXO's revenue for 2027 to be $3,130,599,294, with the lowest ALXO revenue forecast at $3,130,599,294, and the highest ALXO revenue forecast at $3,130,599,294. On average, 1 Wall Street analysts forecast ALXO's revenue for 2028 to be $7,470,918,704, with the lowest ALXO revenue forecast at $7,470,918,704, and the highest ALXO revenue forecast at $7,470,918,704.
In 2029, ALXO is forecast to generate $800,053,942 in revenue, with the lowest revenue forecast at $800,053,942 and the highest revenue forecast at $800,053,942.